Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07006662

Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction

Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction — Recruiting • Oncology • NCT07006662.

📅 09 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07006662
Sponsor
University Hospitals of North Midlands NHS Trust
Start
2026-08-04
ClinicaliQ Trial Snapshot
  • Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction — Recruiting • Oncology • NCT07006662.
  • What is being tested: Identification and mapping of chest wall perforator vessels in relation to anatomical landmarks to guide surgical planning for partial breast reconstruction procedures.
  • Patient eligibility overview: Women requiring partial breast reconstruction (typically following breast-conserving surgery or oncoplastic procedures) with adequate chest wall anatomy suitable for perforator-based flap surgery.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to anatomical landmarks for partial breast reconstruction.

Eligibility Snapshot
  • : * Patients undergoing elective breast surgery * Age ≥ 18 years * Female * BMI ≤ 30 kg/m2 * Willing and able to give fully informed consent, * Willing and able to comply with the study procedures

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Pope pictured for first time since surgery and cancer diagnosis
Oncology · BBC Health · 16 Oct 2026
Pope Francis underwent lung cancer surgery at Gemelli Hospital in Rome; public appearance marks recovery milestone following diagnosis First photographic evidence post-operatively…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Guideline
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable
Oncology · 23 Sep 2026
Ibrutinib combined with R-CHOP is recommended for untreated mantle cell lymphoma patients who are fit enough to undergo stem cell transplantation, offering…
View guideline →
Clinical Brief
Andy Burnham urged to set dementia waiting-time target
Oncology · BBC Health · 17 Sep 2026
Key Takeaways for Clinical Practice An 18-week referral-to-treatment target for dementia has been proposed and endorsed by England's former national cancer director,…
View brief →
Guideline
Nirogacestat for treating desmoid tumours
Oncology · 14 Oct 2026
Nirogacestat is recommended as an option for treating desmoid tumours in adults when surgery is not suitable or has failed, enabling consideration…
View guideline →